Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3295142 | 0.96 | MAPK1 (0.33) | MAPK1CYP4F2CYP4A11DGAT1GRIN2B | |
| SCHEMBL22874559 | 0.94 | TSHR (0.35) | MAPK1CYP4F2CYP4A11DGAT1GRIN2B | |
| SCHEMBL21064071 | 0.94 | TSHR (0.35) | MAPK1CYP4F2CYP4A11DGAT1GRIN2B | |
| SCHEMBL21064053 | 0.94 | TSHR (0.35) | MAPK1CYP4F2CYP4A11DGAT1GRIN2B | |
| SCHEMBL18361370 | 0.94 | TSHR (0.35) | MAPK1CYP4F2CYP4A11DGAT1GRIN2B | |
| SCHEMBL3296871 | 0.94 | TSHR (0.35) | MAPK1CYP4F2CYP4A11DGAT1GRIN2B | |
| SCHEMBL18361332 | 0.94 | TSHR (0.35) | MAPK1CYP4F2CYP4A11DGAT1GRIN2B | |
| Formic Acid SCHEMBL27991273 | 0.92 | GRIN2B (0.31) | GRIN2BGRIN2C | |
| SCHEMBL2312894 | 0.91 | MAPK1 (0.34) | MAPK1CYP4F2CYP4A11DGAT1 | |
| Formic Acid SCHEMBL27634168 | 0.88 | GRIN2B (0.31) | GRIN2BGRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139158-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| EP-3237411-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-06-09 | — | — | US | disclosed |
| US-20200190072-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10392372-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180369209-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2018-12-27 | — | — | US | disclosed |
| CN-109020961-A | Antiviral compound | 吉利德制药有限责任公司 | 2018-12-18 | — | — | CN | disclosed |
| EP-3393465-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | Proteostasis Therapeutics, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| CN-104230900-B | Antiviral compound | 吉利德制药有限责任公司 | 2018-10-19 | — | — | CN | disclosed |
| US-20170369480-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| WO-2017112853-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| CN-106588890-A | Antiviral compounds | 吉利德制药有限责任公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-104016971-B | Antiviral compound | PHARMASSET INC. (US) | 2016-05-25 | — | — | CN | disclosed |
| US-20090298894-A1 | AMINO ACID COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369209-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | SMPD1, ELANE, SMPD2 | MAPK1 4841/4885CYP4F2 1957/4885CYP4A11 843/4885 |
| US-20240139158-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | SMPD1, ELANE, SMPD2 | MAPK1 4841/4885CYP4F2 1957/4885CYP4A11 843/4885 |
| US-20170369480-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, SCNN1B, SCNN1G | MAPK1 4625/4885CYP4F2 4343/4885CYP4A11 4184/4885 |
| US-10392372-B2 | Compounds, compositions, and methods for increasing CFTR activity | CFTR, SCNN1B, SCNN1G | MAPK1 4625/4885CYP4F2 4343/4885CYP4A11 4184/4885 |
| US-20090298894-A1 | AMINO ACID COMPOUNDS | S1PR1, S1PR2, S1PR5 | MAPK1 1118/4885CYP4F2 3118/4885CYP4A11 2808/4885 |
| US-20200190072-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, SCNN1B, SCNN1G | MAPK1 4625/4885CYP4F2 4343/4885CYP4A11 4184/4885 |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | SMPD1, ELANE, SMPD2 | MAPK1 4841/4885CYP4F2 1957/4885CYP4A11 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.